Kolexia
Zerdoud Slimane
Médecine nucléaire
Oncopole Toulouse
Toulouse, France
124 Activités
6 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la thyroïde Carcinomes Maladies de la thyroïde Métastase tumorale Métastase lymphatique Carcinome papillaire Carcinome anaplasique de la thyroïde Tumeurs de la prostate Tumeurs du col de l'utérus

Industries

Eisai
14 collaboration(s)
Dernière en 2022
Lilly
4 collaboration(s)
Dernière en 2021
Ipsen
3 collaboration(s)
Dernière en 2023
Merck-Serono
2 collaboration(s)
Dernière en 2023

Dernières activités

Impact d’une thérapie adjuvante à l’iode radioactif versus surveillance active post-reprise ganglionnaire des récidives de cancer thyroïdien papillaire
10e Journées Francophones de Médecine nucléaire - Biarritz   01 mars 2024
Diffuse Bone Uptake of 131 I and Effect on Blood Counts in a Patient With Papillary Thyroid Carcinoma and Chronic Lymphocytic Leukemia.
Clinical nuclear medicine   09 février 2024
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
Thyroid : official journal of the American Thyroid Association   01 novembre 2023
Estimabl2 trial: Thyroidectomy without radioiodine in patients with low-risk thyroid cancer, 5 years of follow-up
39e congrès de la Société Française d'Endocrinologie 2023   01 octobre 2023
INTERMEDIATE: Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
Essai Clinique (Centre François-Baclesse)   06 septembre 2023
Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.
Trials   11 juillet 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   06 juillet 2023
ESTIMABL3: ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
Essai Clinique (Gustave-Roussy)   17 mai 2023
ESTIMABL2: Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Essai Clinique (Gustave-Roussy)   16 mai 2023
Erratum to 'Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes' The Breast (2023) 102-109.
Breast (Edinburgh, Scotland)   10 mai 2023